Mortality Among Injecting Drugs Users - A Follow-up Study Of Injecting Drug User Cohorts.
Funder
National Health and Medical Research Council
Funding Amount
$47,500.00
Summary
This study will follow-up injecting drug users that participated in research in the 1990s and 2000s to examine mortality rates in these groups over time. Identifying information from these studies will be cross-referenced with National Death Index data to determine participants that died and the dates of their death. This study will be the first in Australia to determine mortality rates over time in a defined cohort of injecting drug users outside drug treatment settings. Studying a defined grou ....This study will follow-up injecting drug users that participated in research in the 1990s and 2000s to examine mortality rates in these groups over time. Identifying information from these studies will be cross-referenced with National Death Index data to determine participants that died and the dates of their death. This study will be the first in Australia to determine mortality rates over time in a defined cohort of injecting drug users outside drug treatment settings. Studying a defined group overcomes some of the problems associated with mortality rate estimates based simply on the number of injecting drug-related deaths. Although the number of deaths can be found, the number of people at risk of injecting drug-related death is unclear because of the hidden nature of drug use and the dynamic characteristics of drug use and drug markets. The examination of mortality trends among injecting drug users over time can provide insights regarding changes in drug use patterns and markets. For example, this study will examine changes in injecting drug use mortality across periods of high heroin availability in the late '90s and periods of interrupted heroin supply - the heroin 'drought' - from 2000 onwards. In addition, factors related to injecting drug-related mortality can be explored by comparing the characteristics of injecting drug users that died and those that survived, such as drug use and drug treatment histories, co-morbidities such as mental illness and socio-demographic backgrounds. This information can inform overdose prevention and harm reduction strategies by identifying individuals most at risk of injecting drug-related mortality. This study will also draw attention to the significant public health burden of injecting drug use. In addition, by comparing the results from this study with other similar studies from overseas, we can more reliably compare mortality among groups of Australian injecting drug users with their peers in other countries.Read moreRead less
Investigating The Relationships Between Cannabis And Other Drug Use, Mental Health, Early-life Factors And Life-course Outcomes: Integrative Analyses Of Data From Four Australasian Cohort Studies
Funder
National Health and Medical Research Council
Funding Amount
$292,097.00
Summary
The current study will be the first of its kind to use integrative data analyses _ a highly innovative approach _ to pool data from four large and long-running Australasian cohort studies to better understand the link between cannabis use and later-life outcomes. Dramatically improved knowledge of these relationships will create a clearer picture of the interventions required to reduce the harms associated with cannabis use.
Injecting Drug Use, Incarceration, Infection: Investigating Opportunities For Public Health Interventions In Disadvantaged Populations
Funder
National Health and Medical Research Council
Funding Amount
$329,564.00
Summary
New knowledge required to address infectious diseases and mental illness among two disadvantaged and overlapping groups -people who inject drugs (PWID) and prisoners – will be produced: Cross sectional and longitudinal studies will examine HIV risk in specific populations; A system to track the emergence of injecting will be developed; The global scale of mental illness and TB among PWID will be determined; and how to improve coverage and delivery of TB prevention and treatment will be explored.
Prevention Of Multi-drug Resistant Tuberculosis In A High Prevalence Setting: ‘Connecting The DOTS’ In Vietnam
Funder
National Health and Medical Research Council
Funding Amount
$3,382,020.00
Summary
The close contacts of people with multi-drug resistant tuberculosis (MDR-TB) have a high risk of developing the disease. The V-QUIN MDR-TB Trial will evaluate the effectiveness of an oral antibiotic (levofloxacin) in preventing drug resistant TB among infected household contacts of TB patients. Household contacts from 10 Provinces in Vietnam will be randomly allocated to receive six-months of either levofloxacin or a placebo, and then followed for two years to see if they develop tuberculosis.
Reducing The Burden Of Alcohol And Other Drug Use In Australia
Funder
National Health and Medical Research Council
Funding Amount
$250,805.00
Summary
Innovative research undertaken during the Fellowship program will provide new evidence of how best to respond to alcohol and other drug use. Partnerships with policymakers will ensure this evidence underpins Australian alcohol and other drug policy.
Impact Of An Ivermectin Mass Drug Administration Program Against Endemic Scabies And Strongyloidiasis
Funder
National Health and Medical Research Council
Funding Amount
$1,289,786.00
Summary
Overseas studies suggest sustainable and long term benefits can be obtained through the use of ivermectin in mass drug administration programs to control parasitic infections. Our study will be a critical first step in establishing if such a program can be successful in a remote Indigenous community setting, where the disease burden from scabies and strongyloidiasis (threadworm infections) is very high.
Risk Of Hepatitis C Reinfection Among People With Current Injecting Drug Use Following Successful HCV Treatment
Funder
National Health and Medical Research Council
Funding Amount
$2,245,228.00
Summary
In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs ....In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.Read moreRead less